Inhibrx Bennfentes tulajdonlás
Mi az Inhibrx Bennfentes tulajdonlás?
A Bennfentes tulajdonlás az Inhibrx, Inc. - 31.49%
Mi a Bennfentes tulajdonlás meghatározása?
A bennfentes tulajdonjog kiszámítása a bennfentesek tulajdonában lévő részvények (részvényesek, akik a vállalat több mint 5% -át, vagy a vállalat tisztségviselőjét vagy igazgatóját birtokolják) teljes létszámával, osztva a teljes részvénykivonással.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Bennfentes tulajdonlás a Health Care szektor a NASDAQ-on cégekben a Inhibrx -hoz képest
Mit csinál Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
bennfentes tulajdonlás -hoz hasonló cégek Inhibrx
- Damstra Ltd nak Bennfentes tulajdonlás 31.45% van
- Kalina Power nak Bennfentes tulajdonlás 31.45% van
- Chamberlin plc nak Bennfentes tulajdonlás 31.45% van
- Touax SCA nak Bennfentes tulajdonlás 31.45% van
- eGain Corp nak Bennfentes tulajdonlás 31.46% van
- BiVictriX Therapeutics plc nak Bennfentes tulajdonlás 31.48% van
- Inhibrx nak Bennfentes tulajdonlás 31.49% van
- Super Retail nak Bennfentes tulajdonlás 31.49% van
- RE Royalties nak Bennfentes tulajdonlás 31.50% van
- Andritz AG nak Bennfentes tulajdonlás 31.50% van
- OMV AG nak Bennfentes tulajdonlás 31.50% van
- Recticel SA/NV nak Bennfentes tulajdonlás 31.51% van
- Delivery Hero SE nak Bennfentes tulajdonlás 31.51% van